**ClearPoint Neuro Announces Expanded International Regulatory Approvals for Key Therapy Delivery Product** Solana Beach, California - October 6, 2025 - ClearPoint Neuro, Inc. (NASDAQ: CLPT), a global leader in device, cell, and gene therapy delivery for brain and spine applications, has announced expanded regulatory approvals for its precision therapy delivery product in Canada, Hong Kong, and Taiwan. With these new clearances, ClearPoint Neuro's products are now approved for clinical use in 34 countries worldwide. These regulatory milestones are expected to simplify regional clinical trial design and help BioPharma partners accelerate development and commercialization of new gene and cell therapies. The company highlighted that its extensive global regulatory track record aims to reduce technical and surgical risks, while de-risking pathways for partners seeking global scale and standardization. There is no mention of grant or funding awards in this announcement, and the expanded regulatory approvals apply specifically to ClearPoint Neuro's products.